In the long and arduous struggle against human beings and disease, the birth and development of antibacterial drugs is like a vast myth of legend, engraving the wisdom and unfailing exploration of countless scientists, witnessing the transformation from accidental encounters to being a firm defence against life, completely recasting the fate of humankind in its response to bacterial infections.
The story begins on the summer of 1928, when the British scientist Fleming returned from a seemingly normal rewrite of medical history, and in a messy laboratory, he came across a fungus culturer contaminated with fungus, and it’s amazing that around the fungus there was a circle of “bacterium rings”, bacteria stopped growing, as if it was magic. This discovery, which allowed penicillin to enter the horizon, and penicillin’s early luminum, which was like a “doctrine” in World War II, despite its limited purity and low productivity, brought back to life a new era of antibacterial drugs for many soldiers infected with the wound and dying. For the first time, people saw a microbial “synthesis” of magic checks and balances that ignited global scientific enthusiasm for natural antibacterial substances.
As research deepens, scientists are not content with natural extraction limitations and start the process of synthetic antibacterials. In the 1930s, sulfamide-type drugs came into play, which originated in the dye industry, and German scientist Domack discovered the extraordinary effect of the streptocycoccus infection, and follow-up studies revealed that its metabolic sulfamide inhibits the synthesis of bacterial folic acid and interferes with the “supply of raw materials” for bacterian growth, from pneumonia, urinary systems to epidemic meningitis, and the widespread use of sulfamide-like drugs, which became the “primary force” of the infection at that time, more crucially, which means that humans, with chemical synthesis intelligence, can proactively design and manufacture anti-septic “weapons” and anti-stomune “assemblies” amplification.
When penicillin began the Golden Age, scientists dug deep around its structure, its mechanisms of action, and ushered in the prosperity of the “large family” of beta-nimamine antibiotics. Head enzyme has evolved from the first generation to the fifth generation, and has evolved from antibacterial spectrogen to a more effective response to resistant bacteria, such as head-strangling, which is an efficient antibacteria in the common respiratory tract, and subsequent generations of euphemisms extending to the chromoacella “fortress” for complex abdominal and urinary infections; in the same period, carbon pyroacin was born, and the amitamines and meropenans were made to “mether” through hyperspecies, strong antibacteria, particularly in the case of multi-resistant strains, and became a serious disease infection with “saving rice straw”, protecting vulnerable life in the ICSU wards and building a layer defence line at antibacterial positions.
But bacteria is “silent,” and the drug-resistant crisis has led to the development of new antibacterials. At the end of the 20th century, Lysineamine, a drug of phenolone, appeared to respond to “superbacterials” such as methoxysilin-yellow grapepluccus (MRSA), which uniquely inhibits the beginning of the synthesis of bacterial proteins, offers no “breathing” opportunities for drug-resistant bacteria, treats skin soft tissues, pulmonary incorrigible infections, fills the treatment gap for drug-resistant bacteria and highlights the scientific “precision blow” approach.
In the twenty-first century, anti-bacterial drug exploration has moved towards a plural integration. Vegetable cactus therapy, “retrogent back-surgery”, with the use of muccultoids capable of deciphering bacteria, matching strains from sewage, soil-precision screening, treatment of drug-resistant tuberculosis, green bacterium infection, and co-ordination with traditional antibiotics, as well as antibacterial candidates from marine organisms and natural plant extracts, such as deep-sea sponges, to extract antibacterial substances, optimized by modern biotechnology, and develop antibacteria “New Frontiers” as a future reserve.
Back in the past, antibacterial drugs have been found in occasional laboratories to be chemically synthesized, structurally improved and resistant to multi-dimensional innovations, each step being a scientific relay, and in the future, in the face of the ever-evolving bacteria, global collaboration, basic research and clinical transformations, will perpetuate antibacteric “goods” legends and defend human health “clean soil”.
